Anthony Petrone
Stock Analyst at Mizuho
(3.84)
# 477
Out of 4,804 analysts
161
Total ratings
48.31%
Success rate
6.45%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALC Alcon | Maintains: Outperform | $115 → $120 | $89.99 | +33.35% | 9 | Mar 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $54 → $58 | $45.87 | +26.44% | 2 | Mar 6, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $60 | $35.72 | +67.97% | 8 | Feb 26, 2025 | |
| GKOS Glaukos | Upgrades: Outperform | $140 → $200 | $93.55 | +113.79% | 7 | Feb 19, 2025 | |
| HOLX Hologic | Maintains: Outperform | $90 → $87 | $59.31 | +46.69% | 8 | Nov 5, 2024 | |
| TFX Teleflex | Maintains: Neutral | $275 → $250 | $135.16 | +84.97% | 7 | Nov 1, 2024 | |
| BSX Boston Scientific | Maintains: Outperform | $100 → $110 | $96.77 | +13.67% | 8 | Oct 24, 2024 | |
| ABT Abbott Laboratories | Maintains: Neutral | $115 → $130 | $127.04 | +2.33% | 4 | Oct 17, 2024 | |
| ADMA ADMA Biologics | Maintains: Buy | $12 → $14 | $19.39 | -27.80% | 6 | Jun 20, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $65 → $70 | $34.52 | +102.78% | 6 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $55 | $15.87 | +246.57% | 7 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $100 | $100.16 | -0.16% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $64.98 | +61.59% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $105 | $69.90 | +50.21% | 7 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $215 | $216.44 | -0.67% | 15 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $250 | $153.81 | +62.54% | 6 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $7.16 | +95.53% | 4 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $103 → $115 | $77.90 | +47.63% | 14 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $98 | $85.28 | +14.92% | 4 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $522.95 | -25.42% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $83.90 | -20.14% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $115 | $61.03 | +88.43% | 14 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $103.44 | +69.18% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $8.69 | +187.69% | 3 | May 13, 2020 |
Alcon
Mar 28, 2025
Maintains: Outperform
Price Target: $115 → $120
Current: $89.99
Upside: +33.35%
Tarsus Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $45.87
Upside: +26.44%
LivaNova
Feb 26, 2025
Maintains: Outperform
Price Target: $70 → $60
Current: $35.72
Upside: +67.97%
Glaukos
Feb 19, 2025
Upgrades: Outperform
Price Target: $140 → $200
Current: $93.55
Upside: +113.79%
Hologic
Nov 5, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $59.31
Upside: +46.69%
Teleflex
Nov 1, 2024
Maintains: Neutral
Price Target: $275 → $250
Current: $135.16
Upside: +84.97%
Boston Scientific
Oct 24, 2024
Maintains: Outperform
Price Target: $100 → $110
Current: $96.77
Upside: +13.67%
Abbott Laboratories
Oct 17, 2024
Maintains: Neutral
Price Target: $115 → $130
Current: $127.04
Upside: +2.33%
ADMA Biologics
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $19.39
Upside: -27.80%
Establishment Labs Holdings
Jun 6, 2024
Maintains: Buy
Price Target: $65 → $70
Current: $34.52
Upside: +102.78%
May 8, 2024
Maintains: Buy
Price Target: $53 → $55
Current: $15.87
Upside: +246.57%
May 3, 2024
Maintains: Buy
Price Target: $90 → $100
Current: $100.16
Upside: -0.16%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $64.98
Upside: +61.59%
Apr 11, 2024
Maintains: Buy
Price Target: $95 → $105
Current: $69.90
Upside: +50.21%
Mar 27, 2024
Maintains: Buy
Price Target: $215
Current: $216.44
Upside: -0.67%
Mar 27, 2024
Maintains: Buy
Price Target: $250
Current: $153.81
Upside: +62.54%
Mar 1, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $7.16
Upside: +95.53%
Mar 1, 2024
Maintains: Buy
Price Target: $103 → $115
Current: $77.90
Upside: +47.63%
Feb 21, 2024
Maintains: Buy
Price Target: $95 → $98
Current: $85.28
Upside: +14.92%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $522.95
Upside: -25.42%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $83.90
Upside: -20.14%
Feb 8, 2023
Maintains: Buy
Price Target: $110 → $115
Current: $61.03
Upside: +88.43%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $103.44
Upside: +69.18%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $8.69
Upside: +187.69%